US 12,263,247 B2
Inhalable compositions for use in the treatment of pulmonary diseases
Oliver Denk, Munich (DE)
Assigned to Breath Therapeutics GmbH, Munich (DE)
Filed by Breath Therapeutics GmbH, Munich (DE)
Filed on Dec. 21, 2023, as Appl. No. 18/391,712.
Application 18/391,712 is a continuation of application No. 17/865,426, filed on Jul. 15, 2022, granted, now 11,890,376.
Application 17/865,426 is a continuation of application No. 17/298,603, granted, now 11,419,819, issued on Aug. 23, 2022, previously published as PCT/EP2019/083470, filed on Dec. 3, 2019.
Claims priority of application No. 18210255 (EP), filed on Dec. 4, 2018.
Prior Publication US 2024/0122852 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/26 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 38/13 (2006.01); A61K 47/24 (2006.01); A61M 15/00 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 9/0078 (2013.01); A61K 38/13 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61M 15/0085 (2013.01)] 27 Claims
OG exemplary drawing
 
1. A method of delaying the onset or treatment of a pulmonary disease or condition in a subject, the method comprising administering a pharmaceutical composition comprising a therapeutically effective amount of cyclosporine A in liposomally solubilized form to the subject,
wherein the composition is a liquid composition comprising an aqueous liquid vehicle,
wherein the pharmaceutical composition is administered to the subject by a nebulizer, the nebulizer comprising:
a) an aerosol generator adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter of up to about 4.0 um as measured with a 0.9% (w/v) aqueous solution of sodium chloride;
b) a chamber having a volume in the range of from about 50 to about 150 ml; and
c) a mouthpiece;
wherein the mouthpiece comprises:
a body; and
an exhalation filter comprising a filter base;
wherein the body and the filter base are an integrated one-piece unit.